[1] Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology, 2014, 60: 715-735.
[2] Cordoba J, Ventura-Cots M, Simon-Talero M, et al. Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF). J Hepatol, 2014, 60: 275-281.
[3] Reuter B, Walter K, Bissonnette J, et al. Assessment of the spectrum of hepatic encephalopathy: A multicenter study. Liver Transpl, 2018, 24: 587-594.
[4] Hassanein T, Blei A T, Perry W, et al. Performance of the hepatic encephalopathy scoring algorithm in a clinical trial of patients with cirrhosis and severe hepatic encephalopathy. Am J Gastroenterol, 2009, 104: 1392-1400.
[5] Rockey DC, Vierling JM, Mantry P, et al. Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology, 2014, 59: 1073-1083.
[6] Bajaj JS, Frederick RT, Bass NM, et al. Overt hepatic encephalopathy: development of a novel clinician reported outcome tool and electronic caregiver diary. Metab Brain Dis, 2016, 31: 1081-1093.
[7] Thomsen KL, Macnaughtan J, Tritto G, et al. Clinical and Pathophysiological Characteristics of Cirrhotic Patients with Grade 1 and Minimal Hepatic Encephalopathy. PLoS One, 2016, 11(1): e146076.
[8] 徐小元,丁惠国,李文刚,等. 肝硬化肝性脑病诊疗指南. 中华肝脏病杂志, 2018, 26: 721-736.
[9] Sawhney R, Holland-Fischer P, Rosselli M, et al. Role of ammonia, inflammation, and cerebral oxygenation in brain dysfunction of acute-on-chronic liver failure patients. Liver Transpl, 2016, 22: 732-742.
[10] Joshi D, O'Grady J, Patel A, et al. Cerebral oedema is rare in acute-on-chronic liver failure patients presenting with high-grade hepatic encephalopathy. Liver Int, 2014, 34: 362-366.
[11] O'Leary J G, Reddy K R, Garcia-Tsao G, et al. NACSELD acute-on-chronic liver failure (NACSELD-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis. Hepatology, 2018, 67: 2367-2374.
[12] Kril J J, Butterworth R F. Diencephalic and cerebellar pathology in alcoholic and nonalcoholic patients with end-stage liver disease. Hepatology, 1997, 26: 837-841.
[13] De Chiara F, Heeboll S, Marrone G, et al. Urea cycle dysregulation in non-alcoholic fatty liver disease. J Hepatol, 2018, 69: 905-915.
[14] Seo SW, Gottesman RF, Clark JM, et al. Nonalcoholic fatty liver disease is associated with cognitive function in adults. Neurology, 2016, 86: 1136-1142.
[15] Weinstein G, Davis-Plourde K, Himali JJ, et al. Non-alcoholic fatty liver disease, liver fibrosis score and cognitive function in middle-aged adults: The Framingham Study. Liver Int, 2019, 39: 1713-1721.
[16] Grover VP, Pavese N, Koh SB, et al. Cerebral microglial activation in patients with hepatitis C: in vivo evidence of neuroinflammation. J Viral Hepat, 2012, 19: e89-e96.
[17] Kalaitzakis E, Olsson R, Henfridsson P, et al. Malnutrition and diabetes mellitus are related to hepatic encephalopathy in patients with liver cirrhosis. Liver Int, 2007, 27: 1194-1201.
[18] Tapper EB, Parikh ND, Sengupta N, et al. A risk score to predict the development of hepatic encephalopathy in a population-based cohort of patients with cirrhosis. Hepatology, 2018, 68: 1498-1507.
[19] Dasarathy S, Mookerjee RP, Rackayova V, et al. Ammonia toxicity: from head to toe? Metab Brain Dis, 2017, 32: 529-538.
[20] Davuluri G, Allawy A, Thapaliya S, et al. Hyperammonaemia-induced skeletal muscle mitochondrial dysfunction results in cataplerosis and oxidative stress. J Physiol, 2016, 594: 7341-7360.
[21] Gorg B, Qvartskhava N, Bidmon HJ, et al. Oxidative stress markers in the brain of patients with cirrhosis and hepatic encephalopathy. Hepatology, 2010, 52: 256-265.
[22] Bosoi CR, Tremblay M, Rose CF. Induction of systemic oxidative stress leads to brain oedema in portacaval shunted rats. Liver Int, 2014, 34: 1322-1329.
[23] Mcmillin M, Frampton G, Grant S, et al. Bile Acid-Mediated Sphingosine-1-Phosphate Receptor 2 Signaling Promotes Neuroinflammation during Hepatic Encephalopathy in Mice. Front Cell Neurosci, 2017, 11: 191.
[24] Bossen L, Gines P, Vilstrup H, et al. Serum sodium as a risk factor for hepatic encephalopathy in patients with cirrhosis and ascites. J Gastroenterol Hepatol, 2019, 34: 914-920.
[25] Rose CF, Amodio P, Bajaj JS, et al. Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy. J Hepatol, 2020, 73: 1526-1547.
[26] Dabrowska K, Skowronska K, Popek M, et al. Roles of Glutamate and Glutamine Transport in Ammonia Neurotoxicity: State of the Art and Question Marks. Endocr Metab Immune Disord Drug Targets, 2018, 18: 306-315.
[27] Gorg B, Karababa A, Haussinger D. Hepatic Encephalopathy and Astrocyte Senescence. J Clin Exp Hepatol, 2018, 8: 294-300.
[28] Chen Y, Ji F, Guo J, et al. Dysbiosis of small intestinal microbiota in liver cirrhosis and its association with etiology. Sci Rep, 2016, 6: 34055.
[29] Bajaj J S, Heuman D M, Hylemon P B, et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol, 2014, 60: 940-947.
[30] Montano-Loza AJ, Meza-Junco J, Prado CM, et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol, 2012, 10: 166-173, 171-173.
[31] Nardelli S, Lattanzi B, Torrisi S, et al. Sarcopenia Is Risk Factor for Development of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt Placement. Clin Gastroenterol Hepatol, 2017, 15: 934-936.
[32] Weiss N, Thabut D. Neurological Complications Occurring After Liver Transplantation: Role of Risk Factors, Hepatic Encephalopathy, and Acute (on Chronic) Brain Injury. Liver Transpl, 2019, 25: 469-487.
[33] Bemeur C, Cudalbu C, Dam G, et al. Brain edema: a valid endpoint for measuring hepatic encephalopathy? Metab Brain Dis, 2016, 31: 1249-1258. |
